Baseline values were expressed as mean±Sd, changes at TP2 and TP3 as mean±Sd percent change from baseline. We used related Background and Purpose-We compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. Methods-Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment, 3 to 12 hours, and 24±3 hours post-intravenous thrombolysis for analyses of plasminogen, plasminogen activator inhibitor-1, d-dimer, factor V, fibrinogen, and fibrin(ogen) degradation products, in addition to routine coagulation assays. Related sample Wilcoxon signed-rank tests were used to test the within-group changes, and independent Mann-Whitney tests for between-group differences. Results-Thirty patients were included (alteplase=14 and tenecteplase=16) with similar baseline demographics. Compared with baseline, alteplase caused significant hypofibrinogenaemia (P=0.002), prolonged prothrombin time (P=0.011), hypoplasminogenaemia (P=0.001), and lower factor V (P=0.002) at 3 to 12 hours after administration with persistent hypofibrinogenaemia at 24 hours (P=0.011), whereas only minor hypoplasminogenaemia (P=0.029) was seen in the tenecteplase group. Tenecteplase consumed less plasminogen (P<0.001) and fibrinogen (P=0.002) compared with alteplase. Conclusions-In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. 
I
ntravenous thrombolysis with alteplase in acute ischemic stroke improves clinical outcome, but is associated with an absolute risk of fatal intracerebral hemorrhage (ICH) of around 2.7%, ≈7-fold greater odds compared with placebo (odds ratio [95% confidence interval], 7.14 [3.98-12 .79]). 1 In 2 phase 2 trials in acute ischemic stroke, 2, 3 tenecteplase was associated with a trend toward fewer ICH complications.
As a substudy of the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study, we compared the effects of the 2 agents on coagulation and the fibrinolytic system, and explored potential associations with ICH.
Methods
The study protocol of ATTEST has been detailed elsewhere. 3 Eligible thrombolysis candidates within 4.5 hours of onset were randomized to receive a standard alteplase regime (0.9 mg/kg) or 0.25 mg/kg tenecteplase. This substudy was initiated partway through the main trial. All trial participants were approached after it commenced.
Venous blood samples were collected into citrate (final concentration 0.109 mol/L, Greiner Bio-One, Austria) at baseline (prethrombolysis; time point [TP] 1), 3 to 12 hours (TP2), and 24±3 hours (TP3) after the initiation of thrombolysis. Plasma was harvested by centrifugation immediately after sampling and stored at −80°C until analysis. We measured prothrombin time, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products, plasminogen, d-dimer, factor V (FV), plasminogen activator inhibitor-1 activity, and prothrombin fragment 1+2 (F1+2) at 3 TPs, respectively (assay methods are shown in detail in Table I in the online-only data Supplement).
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sample Wilcoxon signed-rank tests to examine the within-groups differences (TP2 versus TP1 and TP3 versus TP1), using a Bonferroni correction to yield a significance level of P<0.025. Between-group effects were explored with independent Mann-Whitney test. An univariate binary logistic regression model was used to explore any association between the change of fibrinogen and ICH.
Results
Of 104 participants in the main ATTEST trial, 30 participated in this substudy (alteplase=14 and tenecteplase=16; Figure I in the online-only data Supplement). Key baseline characteristics were similar between groups (Table) . 
Effects on Coagulation and Fibrinolysis

Association Between ICH and Depletion of Fibrinogen
Six patients had hemorrhage post-thrombolysis (4 with alteplase and 2 with tenecteplase), 4 classified as hemorrhagic infarction 4 1, 1 as hemorrhagic infarction type2, and 1 had a small subarachnoid hemorrhage. None was considered symptomatic using either the second European Co-Operative Acute Stroke Study (ECASS 2) or the Safe Implementation of Thrombolysis for Stroke -Monitoring Study (SITS-MOST) criteria. 5 Fibrinogen level dropped below 1 g/L at TP2 in 2 patients, both of whom received alteplase (2/30, 14%). This low level persisted at TP3 in 1, whose follow-up CT revealed hemorrhagic infarction type2; the other patient's fibrinogen rose to 1.4 g/L at TP3, who had subarachnoid hemorrhage. Binary logistic regression found no association between ICH and the change of fibrinogen between TP2 and TP1 (P=0.37).
Discussion
Tenecteplase has 15-fold higher fibrin specificity than alteplase. 6 High fibrin affinity should translate into greater potency for thrombolysis, while preserving the integrity of systemic coagulation. 7 Acute ischemic stroke trials suggest that tenecteplase may be associated with lower ICH risk with similar or superior recanalization compared with alteplase. 2, 3 In this sample, alteplase caused significant fibrinogen depletion and consumption of plasminogen, and degradation of factor V, whereas tenecteplase did not.
Early degradation of fibrinogen is associated with the occurrence of ICH. Matosevic et al 8 reported that within 6-hours post-thrombolysis, a decrease of ≥2g/L in fibrinogen level was an independent predictor for bleeding of all kinds. Significant hypofibrinogaemia (a decrease of 2 g/L or 50% from baseline) occurs in about one fifth of those receiving intravenous alteplase, whereas a tenecteplase dose escalation study 9 showed no severe hypofibrinogenaemia (fibrinogen <1 g/dL) in any dose (0.1-0.5 mg/kg) tested. Similarly, in our sample, tenecteplase treatment did not cause hypofibrinogenaemia using either of these criteria. We could not replicate an association between hypofibrinogenaemia and ICH, probably because of the small sample.
Limitations of our study include small sample size, variable time of sampling at TP2, and the low incidence of serious ICH (none having parenchymal hemorrhage or symptomatic clinical deterioration attributable to hemorrhage). Nonetheless, we found significant changes in coagulation and fibrinolysis after intravenous alteplase consistent with the literature, and minimal disruption with tenecteplase, consistent with a potentially better safety profile for tenecteplase, with retained fibrinolytic efficacy.
Conclusions
In acute ischemic stroke, tenecteplase caused significantly less disruption to the coagulation and fibrinolytic systems compared 
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with alteplase. This finding was consistent with the trend toward reduced incidence of ICH observed in the ATTEST trial. 
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Fibrin specificity tPA activates plasminogen to plasmin, which breaks fibrin down to fibrin-degradation products. Non-fibrin-selective agents, such as streptokinase or urokinase significantly affect haemostasis by breaking down circulating fibrinogen as well as the fibrin in thrombus 1 . Recombinant tPA (rtPA) more selectively binds to fibrin on the surface of clot, and activates mainly fibrin -bound plasminogen, which results in relatively local fibrinolysis, hence fewer bleeding complication and more targeted lysis. By restricting the activation of plasminogen to the clot surface, systemic plasminogen and fibrinogen pools are preserved to ensure more effective lysis. This property of selective binding to clot fibrin is termed fibrin specificity or affinity, and is approximately 15 fold greater in tenecteplase than alteplase 2 . The expectation that tenecteplase should decrease haemorrhage incidence without comprising efficacy was evidenced by MI thrombolysis studies 3 .
Clauss method of fibrinogen assay
Clauss method 4 , a clot rate assay is the recommended method to analyse fibrinogen level by British Society for Haematology 5 . It is the most sensitive method in detecting low fibrinogen levels and provides the lowest value among the three common used assays by reliably detecting values as low as 0.55g/L with normal plasma 6 .
It is sensitive to heparin therapy and high FDP levels, which can produce falsely lower levels 7 , but can be corrected with simple modification 8 . In an acute MI thrombolysis study using alteplase, compared to sulphite precipitation in fibrinogen measurement, Clauss method is superior and more reliable in detecting hypofibrinogenaemia 9 . A =Alteplase; T=Tenecteplase; TP=Time Point. Baseline values were expressed as mean±SD, the changes at TP2 (3-12 hours post thrombolysis) and TP3 (24±2 hours post thrombolysis) were expressed as mean ±SD % changes from baseline; *laboratory reference value; # P value between the groups; 
